HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe
Given the detrimental effects of HIV-associated anemia on morbidity, we determined factors associated with anemia after 96 weeks of antiretroviral therapy (ART) across age groups. An HIV-positive cohort (n=3,580) of children age 5-14, reproductive age adults 18-49, and older adults ≥50 from two rand...
Gespeichert in:
| Veröffentlicht in: | AIDS research and human retroviruses 2014-06, Vol.30 (6), p.523-530 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 530 |
|---|---|
| container_issue | 6 |
| container_start_page | 523 |
| container_title | AIDS research and human retroviruses |
| container_volume | 30 |
| creator | Jaganath, Devan Walker, A Sarah Ssali, Francis Musiime, Victor Kiweewa, Francis Kityo, Cissy Salata, Robert Mugyenyi, Peter |
| description | Given the detrimental effects of HIV-associated anemia on morbidity, we determined factors associated with anemia after 96 weeks of antiretroviral therapy (ART) across age groups. An HIV-positive cohort (n=3,580) of children age 5-14, reproductive age adults 18-49, and older adults ≥50 from two randomized trials in Uganda and Zimbabwe were evaluated from initiation of therapy through 96 weeks. We conducted logistic and multinomial regression to evaluate common and differential determinants for anemia at 96 weeks on therapy. Prior to initiation of ART, the prevalence of anemia (age 5-11 |
| doi_str_mv | 10.1089/aid.2013.0255 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4046193</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1635037331</sourcerecordid><originalsourceid>FETCH-LOGICAL-c420t-21aef08ebb65b9da26e12c7ff757f054c2acd62efb01610dcdb8d17f0059363b3</originalsourceid><addsrcrecordid>eNpVkTFvFDEQhS0URI5ASRu5TLPH2F7v7aaIFEVAIkWiIRQ01tgeX0xuvRd7jyj_Hh8JEVSveE9vRu9j7IOApYB--IjRLyUItQSp9Su2EIMSTd-CPmAL6PuhkVIOh-xtKT8BYJBSv2GHstXQCZALFi6vvjdYyuQizuQ5JhojcgwzZT50_IHorvAp8fmWMm4fT7mnao0xYZoLR5enUmVNPGNaU-Ex8Zs1Jl87kuc_4mjRPtA79jrgptD7Zz1iN58_fbu4bK6_frm6OL9uXCthbqRACtCTtZ22g0fZkZBuFcJKrwLo1kl0vpMULIj6v3fe9l5UC_SgOmXVETt76t3u7EjeUZozbsw2xxHzo5kwmv-dFG_NevplWmi7Ol0tOHkuyNP9jspsxlgcbTZ1mGlXjOiUBrVSStRo8xT9s0Gm8HJGgNmzMZWN2bMxezY1f_zvby_pvzDUb4twi-g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1635037331</pqid></control><display><type>article</type><title>HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe</title><source>Mary Ann Liebert Online Subscription</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Jaganath, Devan ; Walker, A Sarah ; Ssali, Francis ; Musiime, Victor ; Kiweewa, Francis ; Kityo, Cissy ; Salata, Robert ; Mugyenyi, Peter</creator><creatorcontrib>Jaganath, Devan ; Walker, A Sarah ; Ssali, Francis ; Musiime, Victor ; Kiweewa, Francis ; Kityo, Cissy ; Salata, Robert ; Mugyenyi, Peter ; ARROW Trial ; DART Trial ; for the DART and ARROW Trials</creatorcontrib><description><![CDATA[Given the detrimental effects of HIV-associated anemia on morbidity, we determined factors associated with anemia after 96 weeks of antiretroviral therapy (ART) across age groups. An HIV-positive cohort (n=3,580) of children age 5-14, reproductive age adults 18-49, and older adults ≥50 from two randomized trials in Uganda and Zimbabwe were evaluated from initiation of therapy through 96 weeks. We conducted logistic and multinomial regression to evaluate common and differential determinants for anemia at 96 weeks on therapy. Prior to initiation of ART, the prevalence of anemia (age 5-11 <10.5 g/dl, 12-14 <11 g/dl, adult females <11 g/dl, adult males <12 g/dl) was 43%, which decreased to 13% at week 96 (p<0.001). Older adults had a significantly higher likelihood of anemia compared to reproductive age adults (OR 2.60, 95% CI 1.44-4.70, p=0.002). Reproductive age females had a significantly higher odds of anemia compared to men at week 96 (OR 2.56, 95% CI 1.92-3.40, p<0.001), and particularly a greater odds for microcytic anemia compared to males in the same age group (p=0.001). Other common factors associated with anemia included low body mass index (BMI) and microcytosis; greater increases in CD4 count to week 96 were protective. Thus, while ART significantly reduced the prevalence of anemia at 96 weeks, 13% of the population continued to be anemic. Specific groups, such as reproductive age females and older adults, have a greater odds of anemia and may guide clinicians to pursue further evaluation and management.]]></description><identifier>ISSN: 0889-2229</identifier><identifier>EISSN: 1931-8405</identifier><identifier>DOI: 10.1089/aid.2013.0255</identifier><identifier>PMID: 24506102</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Anemia - epidemiology ; Anti-HIV Agents - adverse effects ; Anti-HIV Agents - therapeutic use ; Child ; Child, Preschool ; Cohort Studies ; Epidemiology ; Female ; HIV Infections - complications ; HIV Infections - drug therapy ; Human immunodeficiency virus ; Humans ; Male ; Middle Aged ; Prevalence ; Randomized Controlled Trials as Topic ; Retrovirus ; Sex Factors ; Time Factors ; Uganda - epidemiology ; Young Adult ; Zimbabwe - epidemiology</subject><ispartof>AIDS research and human retroviruses, 2014-06, Vol.30 (6), p.523-530</ispartof><rights>Copyright 2014, Mary Ann Liebert, Inc. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c420t-21aef08ebb65b9da26e12c7ff757f054c2acd62efb01610dcdb8d17f0059363b3</citedby><cites>FETCH-LOGICAL-c420t-21aef08ebb65b9da26e12c7ff757f054c2acd62efb01610dcdb8d17f0059363b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,3042,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24506102$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jaganath, Devan</creatorcontrib><creatorcontrib>Walker, A Sarah</creatorcontrib><creatorcontrib>Ssali, Francis</creatorcontrib><creatorcontrib>Musiime, Victor</creatorcontrib><creatorcontrib>Kiweewa, Francis</creatorcontrib><creatorcontrib>Kityo, Cissy</creatorcontrib><creatorcontrib>Salata, Robert</creatorcontrib><creatorcontrib>Mugyenyi, Peter</creatorcontrib><creatorcontrib>ARROW Trial</creatorcontrib><creatorcontrib>DART Trial</creatorcontrib><creatorcontrib>for the DART and ARROW Trials</creatorcontrib><title>HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe</title><title>AIDS research and human retroviruses</title><addtitle>AIDS Res Hum Retroviruses</addtitle><description><![CDATA[Given the detrimental effects of HIV-associated anemia on morbidity, we determined factors associated with anemia after 96 weeks of antiretroviral therapy (ART) across age groups. An HIV-positive cohort (n=3,580) of children age 5-14, reproductive age adults 18-49, and older adults ≥50 from two randomized trials in Uganda and Zimbabwe were evaluated from initiation of therapy through 96 weeks. We conducted logistic and multinomial regression to evaluate common and differential determinants for anemia at 96 weeks on therapy. Prior to initiation of ART, the prevalence of anemia (age 5-11 <10.5 g/dl, 12-14 <11 g/dl, adult females <11 g/dl, adult males <12 g/dl) was 43%, which decreased to 13% at week 96 (p<0.001). Older adults had a significantly higher likelihood of anemia compared to reproductive age adults (OR 2.60, 95% CI 1.44-4.70, p=0.002). Reproductive age females had a significantly higher odds of anemia compared to men at week 96 (OR 2.56, 95% CI 1.92-3.40, p<0.001), and particularly a greater odds for microcytic anemia compared to males in the same age group (p=0.001). Other common factors associated with anemia included low body mass index (BMI) and microcytosis; greater increases in CD4 count to week 96 were protective. Thus, while ART significantly reduced the prevalence of anemia at 96 weeks, 13% of the population continued to be anemic. Specific groups, such as reproductive age females and older adults, have a greater odds of anemia and may guide clinicians to pursue further evaluation and management.]]></description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anemia - epidemiology</subject><subject>Anti-HIV Agents - adverse effects</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cohort Studies</subject><subject>Epidemiology</subject><subject>Female</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prevalence</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Retrovirus</subject><subject>Sex Factors</subject><subject>Time Factors</subject><subject>Uganda - epidemiology</subject><subject>Young Adult</subject><subject>Zimbabwe - epidemiology</subject><issn>0889-2229</issn><issn>1931-8405</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkTFvFDEQhS0URI5ASRu5TLPH2F7v7aaIFEVAIkWiIRQ01tgeX0xuvRd7jyj_Hh8JEVSveE9vRu9j7IOApYB--IjRLyUItQSp9Su2EIMSTd-CPmAL6PuhkVIOh-xtKT8BYJBSv2GHstXQCZALFi6vvjdYyuQizuQ5JhojcgwzZT50_IHorvAp8fmWMm4fT7mnao0xYZoLR5enUmVNPGNaU-Ex8Zs1Jl87kuc_4mjRPtA79jrgptD7Zz1iN58_fbu4bK6_frm6OL9uXCthbqRACtCTtZ22g0fZkZBuFcJKrwLo1kl0vpMULIj6v3fe9l5UC_SgOmXVETt76t3u7EjeUZozbsw2xxHzo5kwmv-dFG_NevplWmi7Ol0tOHkuyNP9jspsxlgcbTZ1mGlXjOiUBrVSStRo8xT9s0Gm8HJGgNmzMZWN2bMxezY1f_zvby_pvzDUb4twi-g</recordid><startdate>201406</startdate><enddate>201406</enddate><creator>Jaganath, Devan</creator><creator>Walker, A Sarah</creator><creator>Ssali, Francis</creator><creator>Musiime, Victor</creator><creator>Kiweewa, Francis</creator><creator>Kityo, Cissy</creator><creator>Salata, Robert</creator><creator>Mugyenyi, Peter</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>201406</creationdate><title>HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe</title><author>Jaganath, Devan ; Walker, A Sarah ; Ssali, Francis ; Musiime, Victor ; Kiweewa, Francis ; Kityo, Cissy ; Salata, Robert ; Mugyenyi, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c420t-21aef08ebb65b9da26e12c7ff757f054c2acd62efb01610dcdb8d17f0059363b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anemia - epidemiology</topic><topic>Anti-HIV Agents - adverse effects</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cohort Studies</topic><topic>Epidemiology</topic><topic>Female</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prevalence</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Retrovirus</topic><topic>Sex Factors</topic><topic>Time Factors</topic><topic>Uganda - epidemiology</topic><topic>Young Adult</topic><topic>Zimbabwe - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jaganath, Devan</creatorcontrib><creatorcontrib>Walker, A Sarah</creatorcontrib><creatorcontrib>Ssali, Francis</creatorcontrib><creatorcontrib>Musiime, Victor</creatorcontrib><creatorcontrib>Kiweewa, Francis</creatorcontrib><creatorcontrib>Kityo, Cissy</creatorcontrib><creatorcontrib>Salata, Robert</creatorcontrib><creatorcontrib>Mugyenyi, Peter</creatorcontrib><creatorcontrib>ARROW Trial</creatorcontrib><creatorcontrib>DART Trial</creatorcontrib><creatorcontrib>for the DART and ARROW Trials</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>AIDS research and human retroviruses</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jaganath, Devan</au><au>Walker, A Sarah</au><au>Ssali, Francis</au><au>Musiime, Victor</au><au>Kiweewa, Francis</au><au>Kityo, Cissy</au><au>Salata, Robert</au><au>Mugyenyi, Peter</au><aucorp>ARROW Trial</aucorp><aucorp>DART Trial</aucorp><aucorp>for the DART and ARROW Trials</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe</atitle><jtitle>AIDS research and human retroviruses</jtitle><addtitle>AIDS Res Hum Retroviruses</addtitle><date>2014-06</date><risdate>2014</risdate><volume>30</volume><issue>6</issue><spage>523</spage><epage>530</epage><pages>523-530</pages><issn>0889-2229</issn><eissn>1931-8405</eissn><abstract><![CDATA[Given the detrimental effects of HIV-associated anemia on morbidity, we determined factors associated with anemia after 96 weeks of antiretroviral therapy (ART) across age groups. An HIV-positive cohort (n=3,580) of children age 5-14, reproductive age adults 18-49, and older adults ≥50 from two randomized trials in Uganda and Zimbabwe were evaluated from initiation of therapy through 96 weeks. We conducted logistic and multinomial regression to evaluate common and differential determinants for anemia at 96 weeks on therapy. Prior to initiation of ART, the prevalence of anemia (age 5-11 <10.5 g/dl, 12-14 <11 g/dl, adult females <11 g/dl, adult males <12 g/dl) was 43%, which decreased to 13% at week 96 (p<0.001). Older adults had a significantly higher likelihood of anemia compared to reproductive age adults (OR 2.60, 95% CI 1.44-4.70, p=0.002). Reproductive age females had a significantly higher odds of anemia compared to men at week 96 (OR 2.56, 95% CI 1.92-3.40, p<0.001), and particularly a greater odds for microcytic anemia compared to males in the same age group (p=0.001). Other common factors associated with anemia included low body mass index (BMI) and microcytosis; greater increases in CD4 count to week 96 were protective. Thus, while ART significantly reduced the prevalence of anemia at 96 weeks, 13% of the population continued to be anemic. Specific groups, such as reproductive age females and older adults, have a greater odds of anemia and may guide clinicians to pursue further evaluation and management.]]></abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>24506102</pmid><doi>10.1089/aid.2013.0255</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0889-2229 |
| ispartof | AIDS research and human retroviruses, 2014-06, Vol.30 (6), p.523-530 |
| issn | 0889-2229 1931-8405 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4046193 |
| source | Mary Ann Liebert Online Subscription; MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Adult Age Factors Aged Aged, 80 and over Anemia - epidemiology Anti-HIV Agents - adverse effects Anti-HIV Agents - therapeutic use Child Child, Preschool Cohort Studies Epidemiology Female HIV Infections - complications HIV Infections - drug therapy Human immunodeficiency virus Humans Male Middle Aged Prevalence Randomized Controlled Trials as Topic Retrovirus Sex Factors Time Factors Uganda - epidemiology Young Adult Zimbabwe - epidemiology |
| title | HIV-associated anemia after 96 weeks on therapy: determinants across age ranges in Uganda and Zimbabwe |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T12%3A09%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HIV-associated%20anemia%20after%2096%20weeks%20on%20therapy:%20determinants%20across%20age%20ranges%20in%20Uganda%20and%20Zimbabwe&rft.jtitle=AIDS%20research%20and%20human%20retroviruses&rft.au=Jaganath,%20Devan&rft.aucorp=ARROW%20Trial&rft.date=2014-06&rft.volume=30&rft.issue=6&rft.spage=523&rft.epage=530&rft.pages=523-530&rft.issn=0889-2229&rft.eissn=1931-8405&rft_id=info:doi/10.1089/aid.2013.0255&rft_dat=%3Cproquest_pubme%3E1635037331%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1635037331&rft_id=info:pmid/24506102&rfr_iscdi=true |